Class of 2023
Scientific Area of Expertise: Clinical Oncology, Immunotherapy, Tumor Immunology
For illustrious contributions to novel cancer immunotherapy strategies, such as demonstrating the benefits of checkpoint inhibitor therapy in melanoma; and for leading several pivotal clinical trials, including the phase I clinical trial for ipilimumab and the phase III clinical trial involving the combination of ipilimumab and nivolumab.
*Full-length biography pending